Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 5Neoplasms 3Glioma 3Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Gliosarcoma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Head and Neck Neoplasms 1Ependymoma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Bevacizumab 10Magnetic Resonance Spectroscopy 9Temozolomide 8Cyclophosphamide 8Etoposide 7X-Rays 6Phantoms, Imaging 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Cisplatin 5Radiotherapy 4Irinotecan 4Filgrastim 4Carboplatin 4Biopsy 4Erlotinib Hydrochloride 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2sargramostim 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ependymoma × poly ICLC × Clear all
NCT00058123 2018-08-21

Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
55 enrolled 8 charts
CNS

Astrocytoma, Brain Neoplasms, Ependymoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡